Common cellular and molecular mechanisms underlying Alzheimer's disease and type 2 diabetes: A knowledge-driven approach

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 2, 2014, Pages 247-258

  Gauthaman, Kalamegam ^a   Pushparaj, Peter Natesan ^a,b   Rajeshkumar, Manoharan ^a   Narasimhan, Kothandaraman ^a   Al Qahtani, Mohammed ^a   Cheung, Nam Sang ^c   Manikandan, Jayapal ^a,d  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c DEAKIN UNIVERSITY   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Advanced glycation end products; Alzheimer's disease; Amyloid protein; Inflammation; Type II diabetes mellitus

Indexed keywords

ADVANCED GLYCATION END PRODUCT; APOLIPOPROTEIN E4; CHOLINESTERASE;

ALZHEIMER DISEASE; ARTICLE; AUTOPHAGOSOME; CLUSTER ANALYSIS; DOWN REGULATION; GENE CONTROL; GENE EXPRESSION; HUMAN; INFLAMMATION; MITOCHONDRION; NERVE DEGENERATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; RISK FACTOR; STRESS; ANIMAL; BRAIN; GENETICS; METABOLISM;

ALZHEIMER DISEASE; ANIMALS; BRAIN; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION; HUMANS;

EID: 84916895224     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/18715273113126660138     Document Type: Article

References (96)

1. Duarte AI, Moreira PI, Oliveira CR. Insulin in central nervous system: more than just a peripheral hormone. J Aging Res 2012; 2012: 384017.
2. Matusik P, Dubiel M, Wizner B, et al. Age-related gap in the management of heart failure patients. The National Project of Prevention and Treatment of Cardiovascular Diseases-POLKARD. Cardiol J 2012; 19(2): 146-52.
3. Hegde ML, Mantha AK, Hazra TK, et al. Oxidative genome damage and its repair: implications in aging and neurodegenerative diseases. Mech Ageing Dev 2012; 133(4): 157-68.
4. Glassock RJ, Rule AD. The implications of anatomical and functional changes of the aging kidney: with an emphasis on the glomeruli. Kidney Int 2012; 82(3): 270-7.
5. Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol 1985; 42(11): 1097-105.
6. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007; 3(3): 186-91.
7. Alzheimer A. 2010 Alzheimer's disease facts and figures. Alzheimers Dement 2010; 6(2): 158-94.
8. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55(6): 1577-96.
9. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999; 53(9): 1937-42.
10. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004; 61(5): 661-6.
11. Hassing LB, Johansson B, Nilsson SE, et al. Diabetes mellitus is a risk factor for vascular dementia, but not for Alzheimer's disease: a population-based study of the oldest old. Int Psychogeriatr 2002; 14(3): 239-48.
12. Xu WL, Qiu CX, Wahlin A, Winblad B, Fratiglioni L. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology 2004; 63(7): 1181-6.
13. Kroner Z. The relationship between Alzheimer's disease and diabetes: Type 3 diabetes? Altern Med Rev 2009; 14(4): 373-9.
14. Sims-Robinson C, Kim B, Rosko A, Feldman EL. How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol 2010; 6(10): 551-9.
15. Takeda S, Sato N, Rakugi H, Morishita R. Molecular mechanisms linking diabetes mellitus and Alzheimer disease: beta-amyloid peptide, insulin signaling, and neuronal function. Mol Biosyst 2011; 7(6): 1822-7.
16. Bitel CL, Kasinathan C, Kaswala RH, Klein WL, Frederikse PH. Amyloid-beta and tau pathology of Alzheimer's disease induced by diabetes in a rabbit animal model. J Alzheimers Dis 2012; 32(2): 291-305.
17. Carvalho C, Cardoso S, Correia SC, et al. Metabolic alterations induced by sucrose intake and Alzheimer's disease promote similar brain mitochondrial abnormalities. Diabetes 2012; 61(5): 1234-42.
18. Nicolls MR. The clinical and biological relationship between Type II diabetes mellitus and Alzheimer's disease. Curr Alzheimer Res 2004; 1(1): 47-54.
19. Neumann KF, Rojo L, Navarrete LP, et al. Insulin resistance and Alzheimer's disease: molecular links & clinical implications. Curr Alzheimer Res 2008; 5(5): 438-47.
20. Devi L, Alldred MJ, Ginsberg SD, Ohno M. Mechanisms underlying insulin deficiency-induced acceleration of betaamyloidosis in a mouse model of Alzheimer's disease. PLoS One 2012; 7(3): e32792.
21. Watson GS, Craft S. The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs 2003; 17(1): 27-45.
22. Woods SC, Seeley RJ, Baskin DG, Schwartz MW. Insulin and the blood-brain barrier. Curr Pharm Des 2003; 9(10): 795-800.
23. Havrankova J, Roth J, Brownstein M. Insulin receptors are widely distributed in the central nervous system of the rat. Nature 1978; 272(5656): 827-9.
24. Cole AR, Astell A, Green C, Sutherland C. Molecular connexions between dementia and diabetes. Neurosci Biobehav Rev 2007; 31(7): 1046-63.
25. Saltiel AR. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 2001; 104(4): 517-29.
26. Miyamoto Y, Chen L, Sato M, et al. Hippocampal synaptic modulation by the phosphotyrosine adapter protein ShcC/N-Shc via interaction with the NMDA receptor. J Neurosci 2005; 25(7): 1826-35.
27. Horwood JM, Dufour F, Laroche S, Davis S. Signalling mechanisms mediated by the phosphoinositide 3-kinase/Akt cascade in synaptic plasticity and memory in the rat. Eur J Neurosci 2006; 23(12): 3375-84.
28. Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 2003; 423(6938): 435-9.
29. Beeler N, Riederer BM, Waeber G, Abderrahmani A. Role of the JNK-interacting protein 1/islet brain 1 in cell degeneration in Alzheimer disease and diabetes. Brain Res Bull 2009; 80(4-5): 274-81.
30. Thakur A, Wang X, Siedlak SL, Perry G, Smith MA, Zhu X. c-Jun phosphorylation in Alzheimer disease. J Neurosci Res 2007; 85(8): 1668-73.
31. Takeda S, Sato N, Uchio-Yamada K, et al. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci USA 2010; 107(15): 7036-41.
32. Ke YD, Delerue F, Gladbach A, Gotz J, Ittner LM. Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease. PLoS One 2009; 4(11): e7917.
33. Deramecourt V, Slade JY, Oakley AE, et al. Staging and natural history of cerebrovascular pathology in dementia. Neurology 2012; 78(14): 1043-50.
34. Debette S, Seshadri S, Beiser A, et al. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology 2011; 77(5): 461-8.
35. Tong XK, Lecrux C, Rosa-Neto P, Hamel E. Age-dependent rescue by simvastatin of Alzheimer's disease cerebrovascular and memory deficits. J Neurosci 2012; 32(14): 4705-15.
36. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988; 240(4852): 622-30.
37. Sorci-Thomas M, Prack MM, Dashti N, et al. Apolipoprotein (apo) A-I production and mRNA abundance explain plasma apoA-I and high density lipoprotein differences between two nonhuman primate species with high and low susceptibilities to diet-induced hypercholesterolemia. J Biol Chem 1988; 263(11): 5183-9.
38. Nickerson DA, Taylor SL, Fullerton SM, et al. Sequence diversity and large-scale typing of SNPs in the human apolipoprotein E gene. Genome Res 2000; 10(10): 1532-45.
39. Mahley RW, Huang Y, Weisgraber KH. Putting cholesterol in its place: apoE and reverse cholesterol transport. J Clin Invest 2006; 116(5): 1226-9.
40. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 2007; 39(1): 17-23.
41. Lambert JC, Heath S, Even G, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009; 41(10): 1094-9.
42. Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010; 67(1): 122-31.
43. Castellano JM, Kim J, Stewart FR, et al. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci Transl Med 2011; 3(89): 89ra57.
44. Eichner JE, Dunn ST, Perveen G, et al. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 2002; 155(6): 487-95.
45. Johnson LA, Kim HS, Knudson MJ, et al. Diabetic atherosclerosis in APOE*4 mice: Synergy between lipoprotein metabolism and vascularinflammation. J Lipid Res 2012; 54(2): 386-96.
46. Yamagishi S, Ueda S, Okuda S. Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disorders. Curr Pharm: Des 2007; 13(27): 2832-6.
47. Jakus V, Rietbrock N. Advanced glycation end-products and the progress of diabetic vascular complications. Physiol Res 2004; 53(2): 131-42.
48. Shuvaev VV, Laffont I, Serot JM, et al. Increased protein glycation in cerebrospinal fluid of Alzheimer's disease. Neurobiol Aging 2001; 22(3): 397-402.
49. Tessier FJ. The Maillard reaction in the human body. The main discoveries and factors that affect glycation. Pathol Biol (Paris) 2010; 58(3): 214-9.
50. Valente T, Gella A, Fernandez-Busquets X, Unzeta M, Durany N. Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus. Neurobiol Dis 2010; 37(1): 67-76.
51. Cruz-Sanchez FF, Girones X, Ortega A, Alameda F, Lafuente JV. Oxidative stress in Alzheimer's disease hippocampus: a topographical study. J Neurol Sci 2010; 299(1/2): 163-7.
52. Candela P, Gosselet F, Saint-Pol J, et al. Apical-to-basolateral transport of amyloid-beta peptides through blood-brain barrier cells is mediated by the receptor for advanced glycation end-products and is restricted by P-glycoprotein. J Alzheimers Dis 2010; 22(3): 849-59.
53. Nunomura A, Perry G, Aliev G, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001; 60(8): 759-67.
54. Moreira PI, Carvalho C, Zhu X, Smith MA, Perry G. Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology. Biochim Biophys Acta 2010; 1802(1): 2-10.
55. Tiedge M, Lortz S, Drinkgern J, Lenzen S. Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes 1997; 46(11): 1733-42.
56. Russell JW, Berent-Spillson A, Vincent AM, et al. Oxidative injury and neuropathy in diabetes and impaired glucose tolerance. Neurobiol Dis 2008; 30(3): 420-9.
57. Kaneto H, Matsuoka TA. Involvement of Oxidative Stress in Suppression of Insulin Biosynthesis under Diabetic Conditions. Int J Mol Sci 2012; 13(10): 13680-90.
58. Sun LQ, Zhao J, Zhang TT, et al. Protective effects of Salvianolic acid B on Schwann cells apoptosis induced by high glucose. Neurochem Res 2012; 37(5): 996-1010.
59. Ferreiro E, Baldeiras I, Ferreira IL, et al. Mitochondrialand endoplasmic reticulum-associated oxidative stress in Alzheimer's disease: from pathogenesis to biomarkers. Int J Cell Biol 2012; 2012: 735206.
60. Lovell MA, Ehmann WD, Butler SM, Markesbery WR. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 1995; 45(8): 1594-601.
61. Marcus DL, Thomas C, Rodriguez C, et al. Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease. Exp Neurol 1998; 150(1): 40-4.
62. Keller JN, Schmitt FA, Scheff SW, et al. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 2005; 64(7): 1152-6.
63. Buizza L, Cenini G, Lanni C, et al. Conformational altered p53 as an early marker of oxidative stress in Alzheimer's disease. PLoS One 2012; 7(1): e29789.
64. Akter K, Lanza EA, Martin SA, et al. Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? Br J Clin Pharmacol 2011; 71(3): 365-76.
65. Rubio-Perez JM, Morillas-Ruiz JM. A review: inflammatory process in Alzheimer's disease, role of cytokines. Sci World J 2012; 2012: 756357.
66. Wood H. Alzheimer disease: Prostaglandin E(2) signalling is implicated in inflammation early in the Alzheimer disease course. Nat Rev Neurol 2012; 8(8): 411.
67. Shi J, Wang Q, Johansson JU, et al. Inflammatory prostaglandin E(2) signaling in a mouse model of Alzheimer disease. Ann Neurol 2012; 72(5): 788-98.
68. Vennemann A, Gerstner A, Kern N, et al. PTGS-2-PTGER2/4 signaling pathway partially protects from diabetogenic toxicity of streptozotocin in mice. Diabetes 2012; 61(7): 1879-87.
69. Li Y, Duffy KB, Ottinger MA, et al. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis 2010; 19(4): 1205-19.
70. McClean PL, Parthsarathy V, Faivre E, Holscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci 2011; 31(17): 6587-94.
71. Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci 2000; 20(2): 558-67.
72. Weidner C, de Groot JC, Prasad A, et al. Amorfrutins are potent antidiabetic dietary natural products. Proc Natl Acad Sci USA 2012; 109(19): 7257-62.
73. Reitz C, Tokuhiro S, Clark LN, et al. SORCS1 alters amyloid precursor protein processing and variants may increase Alzheimer's disease risk. Ann Neurol 2011; 69(1): 47-64.
74. Ciarlo E, Massone S, Penna I, et al. An intronic ncRNA-dependent regulation of SORL1 expression affecting Abeta formation is upregulated in post-mortem Alzheimer's disease brain samples. Dis Model Mech: 2012; 6(2): 424-33.
75. Wang HF, Yu JT, Zhang W, et al. SORCS1 and APOE polymorphisms interact to confer risk for late-onset Alzheimer's disease in a Northern Han Chinese population. Brain Res 2012; 1448: 111-6.
76. Paterson AD, Waggott D, Boright AP, et al. Complications Trial/Epidemiology of Diabetes I, Complications Research G. A genome-wide association study identifies a novel major locus for glycemic control in type 1 diabetes, as measured by both A1C and glucose. Diabetes 2010; 59(2): 539-49.
77. Lane RF, St George-Hyslop P, Hempstead BL, et al. Vps10 family proteins and the retromer complex in aging-related neurodegeneration and diabetes. J Neurosci 2012; 32(41): 14080-6.
78. Goodarzi MO, Lehman DM, Taylor KD, et al. SORCS1: a novel human type 2 diabetes susceptibility gene suggested by the mouse. Diabetes 2007; 56(7): 1922-9.
79. Liang X, Slifer M, Martin ER, et al. Genomic convergence to identify candidate genes for Alzheimer disease on chromosome 10. Hum Mutat 2009; 30(3): 463-71.
80. Olgiati P, Politis AM, Papadimitriou GN, De Ronchi D, Serretti A. Genetics of late-onset Alzheimer's disease: update from the alzgene database and analysis of shared pathways. Int J Alzheimers Dis 2011; 2011: 832379.
81. Son SM, Song H, Byun J, et al. Accumulation of autophagosomes contributes to enhanced amyloidogenic APP processing under insulin-resistant conditions. Autophagy 2012; 8(12): 1842-4.
82. Rao AA, Sridhar GR, Das UN. Elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes mellitus and Alzheimer's disease. Med Hypotheses 2007; 69(6): 1272-6.
83. Schliebs R, Arendt T. The cholinergic system in aging and neuronal degeneration. Behav Brain Res 2011; 221(2): 555-63.
84. Ahren B. Autonomic regulation of islet hormone secretion-- implications for health and disease. Diabetologia 2000; 43(4): 393-410.
85. Healy JA, Nilsson KR, Hohmeier HE, et al. Cholinergic augmentation of insulin release requires ankyrin-B. Sci Signal 2010; 3(113): ra19.
86. Pohanka M. Cholinesterases, a target of pharmacology and toxicology. Biomed Pap Med FacUniv Palacky Olomouc Czech Repub 2011; 155(3): 219-29.
87. Holmes C, Ballard C, Lehmann D, et al. Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation. J Neurol Neurosurg Psychiatry 2005; 76(5): 640-3.
88. Kamal MA, Tan Y, Seale JP, Qu X. Targeting BuChE-inflammatory pathway by SK0506 to manage type 2 diabetes and Alzheimer disease. Neurochem Res 2009; 34(12): 2163-9.
89. Tan Y, Kamal MA, Wang ZZ, et al. Chinese herbal extracts (SK0506) as a potential candidate for the therapy of the metabolic syndrome. Clin Sci (Lond) 2011; 120(7): 297-305.
90. Lu SH, Wu JW, Liu HL, et al. The discovery of potential acetylcholinesterase inhibitors: a combination of pharmacophore modeling, virtual screening, and molecular docking studies. J Biomed Sci 2011; 18: 8.
91. Mattson MP. Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol 2000; 1(2): 120-9.
92. Koh CH, Qi RZ, Qu D, et al. U18666A-mediated apoptosis in cultured murine cortical neurons: role of caspases, calpains and kinases. Cell Signal 2006; 18(10): 1572-1583.
93. Koh CH, Peng ZF, Ou K, et al. Neuronal apoptosis mediated by inhibition of intracellular cholesterol transport: microarray and proteomics analyses in cultured murine cortical neurons. J Cell Physiol 2007; 211(1): 63-87.
94. Burns M, Duff K. Cholesterol in Alzheimer's disease and tauopathy. Ann NY Acad Sci 2002; 977: 367-375.
95. Ohm TG, Treiber-Held S, Distl R, et al. Cholesterol and tau protein--findings in Alzheimer's and Niemann Pick C's disease. Pharmacopsychiatry 2003; 36(Suppl 2): S120-S126.
96. Hur J, Lee P, Moon E, et al. Neurite outgrowth induced by spicatoside A, a steroidal saponin, via the tyrosine kinase A receptor pathway. Eur J Pharmacol 2009; 620(1-3): 9-15.